Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma

References

• Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005 Oct 13;353(15):1591–1603.
   PubMed Web of Science ®Google Scholar
• Sekido Y. Molecular pathogenesis of malignant mesothelioma. Carcinogenesis. 2013 Jul;34(7):1413–1419.
   PubMed Web of Science ®Google Scholar
• Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol. 2008 Jun;9(2–3):147–157.
   PubMed Web of Science ®Google Scholar
• Testa JR, Cheung M, Pei J, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nature Genetics. 2011 Aug 28;43(10):1022–1025.
   PubMed Web of Science ®Google Scholar
• Ahmed I, Ahmed Tipu S, Ishtiaq S. Malignant mesothelioma. Pak J Med Sci. 2013 Nov;29(6):1433–1438.
   PubMed Web of Science ®Google Scholar
• Haas AR, Sterman DH. Malignant pleural mesothelioma: update on treatment options with a focus on novel therapies. Clin Chest Med. 2013 Mar;34(1):99–111.
   PubMed Web of Science ®Google Scholar
• Park EK, Takahashi K, Hoshuyama T, et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect. 2011 Apr;119(4):514–518.
   PubMed Web of Science ®Google Scholar
• Bibby AC, Tsim S, Kanellakis N, et al. Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment. Eur Respir Rev. 2016 Dec 1;25(142):472–486.
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016 May 05;14:73.
   PubMed Web of Science ®Google Scholar
• Wong RM, Ianculescu I, Sharma S, et al. Immunotherapy for malignant pleural mesothelioma current status and future prospects. Am J Resp Cell Mol. 2014 May;50(5):870–875.
   PubMed Web of Science ®Google Scholar
• June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Investig. 2007;117(6):1466–1476.
   PubMed Web of Science ®Google Scholar
• Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015 May;3(5):436–443.
   PubMed Web of Science ®Google Scholar
• Doyle C. Combination immunotherapy superior to monotherapy in patients with melanoma. Am Health Drug Benefits. 2015;8(Spec Issue):41–41.
   PubMedGoogle Scholar
• Butterfield LH. Cancer vaccines. Bmj. 2015 Apr 22;350:h988.
   PubMed Web of Science ®Google Scholar
• Kumar C, Kohli S, Bapsy PP, et al. Immune modulation by dendritic-cell-based cancer vaccines. J Biosci. 2017 Mar;42(1):161–173.
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013 Jul 25;39(1):38–48.
   PubMed Web of Science ®Google Scholar
• Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011 Jun 1;17(11):3520–3526.
   PubMed Web of Science ®Google Scholar
• Hammerstrom AE, Cauley DH, Atkinson BJ, et al. Cancer immunotherapy: sipuleucel-T and beyond. Pharmacotherapy. 2011;31(8):813–828.
   PubMed Web of Science ®Google Scholar
• Le DT, Dubensky TW, Brockstedt DG. Clinical development of listeria monocytogenes–based immunotherapies. Semin Oncol. 2012;39(3):311–322.
   PubMed Web of Science ®Google Scholar
• Chiang C-L-L, Coukos G, Kandalaft LE. Whole tumor antigen vaccines: where are we? Vaccines. 2015;3(2):344–372.
   PubMed Web of Science ®Google Scholar
• Guo C, Manjili MH, Subjeck JR, et al. Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res. 2013;119:421–475.
   PubMed Web of Science ®Google Scholar
• Huff V. Wilms’ tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer. 2011 Feb;11(2):111–121.
   PubMed Web of Science ®Google Scholar
• Sugiyama H. WT1 (Wilms’ tumor gene 1): biology and cancer immunotherapy. Jpn J Clin Oncol. 2010 May;40(5):377–387.
   PubMed Web of Science ®Google Scholar
• Wurz GT, Kao CJ, DeGregorio MW. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol. 2016 Jan;8(1):4–31.
   PubMed Web of Science ®Google Scholar
• Hegmans LPJJ, Hemmes A, Aerts JG, et al. Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Resp Crit Care. 2005 May 15;171(10):1168–1177.
   PubMed Web of Science ®Google Scholar
• Hegmans JP, Veltman JD, Lambers ME, et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Resp Crit Care. 2010 Jun 15;181(12):1383–1390.
   PubMed Web of Science ®Google Scholar
• Cornelissen R, Hegmans JP, Maat AP, et al. Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma. Am J Respir Crit Care Med. 2016 May 01;193(9):1023–1031.
   PubMed Web of Science ®Google Scholar
• Krug LM, Dao T, Brown AB, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immun. 2010 Oct;59(10):1467–1479.
   PubMed Web of Science ®Google Scholar
• Powell A, Creaney J, Broornfield S, et al. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer-J Iaslc. 2006 May;52(2):189–197.
   PubMed Web of Science ®Google Scholar
• Jahan T, Hassan R, Alley E, et al. 208O_PR: CRS-207 with chemotherapy (chemo) in malignant pleural mesothelioma (MPM): results from a phase 1b trial. J Thorac. 2016 Apr;11(4 Suppl):S156.
   PubMedGoogle Scholar
• Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther. 2013 Jun;138(3):452–469.
   PubMed Web of Science ®Google Scholar
• Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999 Oct;26(5 Suppl 14):66–73.
   PubMed Web of Science ®Google Scholar
• Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007 Sep 01;13(17):5076–5081.
   PubMed Web of Science ®Google Scholar
• Villena-Vargas J, Adusumilli PS. Mesothelin-targeted immunotherapies for malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012 Nov;1(4):466–471.
   PubMedGoogle Scholar
• Chopra A. 111In-labeled CHX-Aʺ-DTPA-conjugated MORAb-009, a chimeric monoclonal antibody directed against mesothelin. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda, MD; 2004.
   Google Scholar
• Hassan R, Ebel W, Routhier EL, et al. Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin. Cancer Immun. 2007 Dec 19;7:20.
   PubMedGoogle Scholar
• Golfier S, Kopitz C, Kahnert A, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther. 2014 Jun;13(6):1537–1548.
   PubMed Web of Science ®Google Scholar
• Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF-beta in cancer patients. Curr Pharm Biotechnol. 2011 Dec;12(12):2176–2189.
   PubMed Web of Science ®Google Scholar
• Massague J. TGFbeta in cancer. Cell. 2008 Jul 25;134(2):215–230.
   PubMed Web of Science ®Google Scholar
• Stevenson JP, Kindler HL, Papasavvas E, et al. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients. Oncoimmunology. 2013;2(8):e26218.
   PubMed Web of Science ®Google Scholar
• Chames P, Van Regenmortel M, Weiss E, et al. Therapeutic antibodies: successes, limitations and hopes for the future. Brit J Pharmacol. 2009 May;157(2):220–233.
   PubMed Web of Science ®Google Scholar
• Gregoire M. What’s the place of immunotherapy in malignant mesothelioma treatments? Cell Adh Migr. 2010 Jan-Mar;4(1):153–161.
   PubMed Web of Science ®Google Scholar
• Klapper JA, Downey SG, Smith FO, et al. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma - A retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008 Jul 15;113(2):293–301.
   PubMed Web of Science ®Google Scholar
• Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early-stage malignant pleural mesothelioma. Cancer. 1994 Nov 1;74(9):2460–2467.
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Hassan R, Fitzgerald DJ, et al. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res. 2009 Aug 15;15(16):5274–5279.
   PubMed Web of Science ®Google Scholar
• Hassan R, Sharon E, Thomas A, et al. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125. Cancer. 2014 Nov 01;120(21):3311–3319.
   PubMed Web of Science ®Google Scholar
• Hassan R, Cohen SJ, Phillips M, et al. Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res. 2010 Dec 15;16(24):6132–6138.
   PubMed Web of Science ®Google Scholar
• Fujisaka Y, Kurata T, Tanaka K, et al. Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):380–388.
   PubMed Web of Science ®Google Scholar
• Hassan R, Kindler HL, Jahan T, et al. Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res. 2014 Dec 01;20(23):5927–5936.
   PubMed Web of Science ®Google Scholar
• Ho WY, Blattman JN, Dossett ML, et al. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell. 2003 May;3(5):431–437.
   PubMed Web of Science ®Google Scholar
• Lee DW, Barrett DM, Mackall C, et al. The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res. 2012;18(10):2780–2790.
   PubMed Web of Science ®Google Scholar
• Carpenito C, Milone MC, Hassan R, et al. Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. 2009 Mar 03;106(9):3360–3365.
   PubMed Web of Science ®Google Scholar
• Schuberth PC, Hagedorn C, Jensen SM, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013 Aug;11(1):187.
   PubMed Web of Science ®Google Scholar
• Bakker E, Guazzelli A, Krstic-Demonacos M, et al. Current and prospective pharmacotherapies for the treatment of pleural mesothelioma. Expert Opinion Orphan Drugs. 2017 [cited 2017 June 03];5(6):455–465.
   Web of Science ®Google Scholar
• Wu R, Forget MA, Chacon J, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma current status and future outlook. Cancer J. 2012 Mar-Apr;18(2):160–175.
   PubMed Web of Science ®Google Scholar
• Guazzelli A, Bakker E, Krstic-Demonacos M, et al. Anti-CTLA-4 therapy for malignant mesothelioma. Immunotherapy. 2017 Mar;9(3):273–280.
   PubMed Web of Science ®Google Scholar
• Bakker E, Qattan M, Mutti L, et al. The role of microenvironment and immunity in drug response in leukemia. Biochim Biophys Acta. 2016 Mar;1863(3):414–426.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015 Jun 10;33(17):1974–U161.
   PubMed Web of Science ®Google Scholar
• Valk E, Rudd CE, Schneider H. CTLA-4 trafficking and surface expression. Trends Immunol. 2008 Jun;29(6):272–279.
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995 Nov 10;270(5238):985–988.
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996 Mar 22;271(5256):1734–1736.
   PubMed Web of Science ®Google Scholar
• Specenier P. Ipilimumab in melanoma. Expert Rev Anticanc. 2016 Aug;16(8):811–826.
   PubMed Web of Science ®Google Scholar
• Guazzelli A, Hussain M, Krstic-Demonacos M, et al. Tremelimumab for the treatment of malignant mesothelioma. Expert Opin Biol Ther. 2015;15(12):1819–1829.
   PubMed Web of Science ®Google Scholar
• Selby MJ, Engelhardt JJ, Johnston RJ, et al. Preclinical development of ipilimumab and nivolumab combination immunotherapy: mouse tumor models, in vitro functional studies, and cynomolgus macaque toxicology. PLoS One. 2016;11(9):e0161779.
   PubMed Web of Science ®Google Scholar
• Ansell SM. Nivolumab in the treatment of Hodgkin lymphoma. Clin Cancer Res. 2016 Nov;23:1623–1626.
   Web of Science ®Google Scholar
• Beaver JA, Theoret MR, Mushti S, et al. FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma. Clin Cancer Res. 2017 Jan 10.
   Google Scholar
• Kazandjian D, Suzman DL, Blumenthal G, et al. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016 May;21(5):634–642.
   PubMed Web of Science ®Google Scholar
• Chang R, Shirai K. Safety and efficacy of pembrolizumab in a patient with advanced melanoma on haemodialysis. BMJ Case Rep. 2016 Sep 22;2016. Available from: http://casereports.bmj.com/content/2016/bcr-2016-216426.long
   Google Scholar
• Bansal P, Osman D, Gan GN, et al. Recent advances in immunotherapy in metastatic NSCLC. Front Oncol. 2016;6:239.
   PubMed Web of Science ®Google Scholar
• Loo D, Alderson RF, Chen FZ, et al. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin Cancer Res. 2012 Jul 15;18(14):3834–3845.
   PubMed Web of Science ®Google Scholar
• Mao L, Fan T-F, Wu L, et al. Selective blockade of B7-H3 enhances antitumour immune activity by reducing immature myeloid cells in head and neck squamous cell carcinoma. J Cell Mol Med. 2017;n/a-n/a.
   Google Scholar
• Alley EW, Lopez J, Santoro A, et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017 May;18(5):623–630.
   PubMed Web of Science ®Google Scholar
• Calabro L, Morra A, Fonsatti E, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. Lancet Oncol. 2013 Oct;14(11):1104–1111.
   PubMed Web of Science ®Google Scholar
• Calabro L, Morra A, Fonsatti E, et al. Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respir Med. 2015 Apr;3(4):301–309.
   PubMed Web of Science ®Google Scholar
• Quispel-Janssen J, Zago G, Schouten R, et al. OA13.01 A phase II study of nivolumab in malignant pleural mesothelioma (NivoMes): with Translational Research (TR) biopies. J Thorac Oncol. 2017;12(1):SS292–SS293.
   Google Scholar
• Hubbard SR, Miller WT. Receptor tyrosine kinases: mechanisms of activation and signaling. Curr Opin Cell Biol. 2007 Apr;19(2):117–123.
   PubMed Web of Science ®Google Scholar
• Destro A, Ceresoli GL, Falleni M, et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations. Lung Cancer-J Iaslc. 2006 Feb;51(2):207–215.
   PubMed Web of Science ®Google Scholar
• Enomoto Y, Kasai T, Takeda M, et al. Epidermal growth factor receptor mutations in malignant pleural and peritoneal mesothelioma. J Clin Pathol. 2012 Jun;65(6):522–527.
   PubMed Web of Science ®Google Scholar
• Rena O, Boldorini LR, Gaudino E, et al. Epidermal growth factor receptor overexpression in malignant pleural mesothelioma: prognostic correlations. J Surg Oncol. 2011 Nov 01;104(6):701–705.
   PubMed Web of Science ®Google Scholar
• Demirag F, Unsal E, Yilmaz A, et al. Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma. Chest. 2005 Nov;128(5):3382–3387.
   PubMed Web of Science ®Google Scholar
• Jahan T, Gu L, Kratzke R, et al. Vatalanib in malignant mesothelioma: a phase II trial by the cancer and leukemia group B (CALGB 30107). Lung Cancer-J Iaslc. 2012 Jun;76(3):393–396.
   PubMed Web of Science ®Google Scholar
• Dubey S, Janne PA, Krug L, et al. A phase II study of sorafenib in malignant mesothelioma results of cancer and leukemia group B 30307. J Thorac Oncol. 2010 Oct;5(10):1655–1661.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Gootenberg J, Keegan P, et al. FDA drug approval summary: bevacizumab (Avastin (R)) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist. 2007;12(6):713–718.
   PubMed Web of Science ®Google Scholar
• Koukourakis GV, Sotiropoulou-Lontou A. Targeted therapy with bevacizumab (Avastin) for metastatic colorectal cancer. Clin Transl Oncol. 2011 Oct;13(10):710–714.
   PubMed Web of Science ®Google Scholar
• Escudier B, Cosaert J, Jethwa S. Targeted therapies in the management of renal cell carcinoma: role of bevacizumab. Biologics. 2008 09;2(3):517–530.
   PubMedGoogle Scholar
• Della Pepa C, Banerjee S. Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer. Oncotargets Ther. 2014;7:1025–1032.
   PubMed Web of Science ®Google Scholar
• Chu W-M. Tumor necrosis factor. Cancer Lett. 2013 Oct 22;328(2):222–225.
   PubMed Web of Science ®Google Scholar
• Gregorc V, Zucali PA, Santoro A, et al. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J Clin Oncol. 2010 May 20;28(15):2604–2611.
   PubMed Web of Science ®Google Scholar
• Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014 Sep;14(9):598–610.
   PubMed Web of Science ®Google Scholar
• Porta C, Paglino C, Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biologics. 2008 Dec;2(4):601–609.
   PubMedGoogle Scholar
• Kelly WK, O’Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005 Jun 10;23(17):3923–3931.
   PubMed Web of Science ®Google Scholar
• Bronte G, Incorvaia L, Rizzo S, et al. The resistance related to targeted therapy in malignant pleural mesothelioma: why has not the target been hit yet? Crit Rev Oncol Hemat. 2016;107:20–32.
   PubMed Web of Science ®Google Scholar
• Govindan R, Kratzke RA, Herndon JE 2nd, et al. Gefitinib in patients with malignant mesothelioma: a phase II study by the cancer and leukemia group B. Clin Cancer Res. 2005 Mar 15;11(6):2300–2304.
   PubMed Web of Science ®Google Scholar
• Garland LL, Rankin C, Gandara DR, et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a southwest oncology group study. J Clin Oncol. 2007 Jun 10;25(17):2406–2413.
   PubMed Web of Science ®Google Scholar
• Jackman DM, Kindler HL, Yeap BY, et al. Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer. 2008 Aug 15;113(4):808–814.
   PubMed Web of Science ®Google Scholar
• Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol. 2012 Jul 10;30(20):2509–2515.
   PubMed Web of Science ®Google Scholar
• Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet (London, England). 2016 Apr 02;387(10026):1405–1414.
   PubMed Web of Science ®Google Scholar
• Ramalingam SS, Belani CP, Ruel C, et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol. 2009 Jan;4(1):97–101.
   PubMed Web of Science ®Google Scholar
• Vachani A, Moon E, Albelda SM. Gene therapy for mesothelioma. Curr Treat Options Oncol. 2011 Jun;12(2):173–180.
   PubMed Web of Science ®Google Scholar
• van der Most RG, Robinson BWS, Nelson DJ. Gene therapy for malignant mesothelioma: beyond the infant years. Cancer Gene Ther. 2006 Oct;13(10):897–904.
   PubMed Web of Science ®Google Scholar
• Vachani A, Sterman DH, Albelda SM. Cytokine gene therapy for malignant pleural mesothelioma. J Thorac. 2007 Apr;2(4):265–267.
   PubMed Web of Science ®Google Scholar
• Zarogoulidis P, Darwiche K, Sakkas A, et al. Suicide gene therapy for cancer – current strategies. J Genet Syndr Gene Ther. 2013;4:16849.
   PubMedGoogle Scholar
• Qian C, Liu XY, Prieto J. Therapy of cancer by cytokines mediated by gene therapy approach. Cell Res. 2006 Feb;16(2):182–188.
   PubMed Web of Science ®Google Scholar
• Sterman DH, Recio A, Vachani A, et al. Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy. Clin Cancer Res. 2005 Oct 15;11(20):7444–7453.
   PubMed Web of Science ®Google Scholar
• Sterman DH, Kanther M. A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses (vol 13, pg 4456, 2007). Clin Cancer Res. 2007 Sep 1;13(17):4456–4466.
   PubMed Web of Science ®Google Scholar
• Nabavi N, Bennewith KL, Churg A, et al. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment. Genes Cancer. 2016 Nov;7(11–12):340–354.
   PubMedGoogle Scholar
• Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma. J Pathol. 2001 Apr;193(4):468–475.
   PubMed Web of Science ®Google Scholar
• Tan A, Porcher R, Crequit P, et al. Differences in treatment effect size between overall survival and progression-free survival in immunotherapy trials: a meta-epidemiologic study of trials with results posted at clinicaltrials.gov. J Clin Oncol. 2017 Apr 04;JCO2016712109:1686–1694.
   Google Scholar
• Abola MV, Prasad V. The use of superlatives in cancer research. Jama Oncol. 2016 Jan;2(1):139–141.
   PubMed Web of Science ®Google Scholar
• Feig C, Jones JO, Kraman M, et al. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212–20217.
   PubMed Web of Science ®Google Scholar